STAG2 and lung adenocarcinoma: As an additional control, we identified alternative splicing events significantly associated with STAG2 mutations in lung adenocarcinoma and AML, as STAG2 is not expected to be a splicing regulator and it is mutated at a similar frequency in both cancer types.